Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three Semi-Critical Reprocessed SUDs Dropped From 510(k)-Exempt List

This article was originally published in The Gray Sheet

Executive Summary

Reprocessors of three types of semi-critical single-use devices must file 510(k)s with validation data by mid-July of 2005 under an FDA rule implementing certain provisions of MDUFMA

You may also be interested in...



AdvaMed Seeks Additions To MDUFMA Reuse Lists, Criticizes Review Criteria

The Association of Medical Device Reprocessors will meet with FDA Sep. 12 to discuss the agency's validation guidance, according to AMDR reps

Device Reuse: 510(k) Exemptions Terminated, Validation Guidance Awaited

FDA is retaining its 510(k)-exempt status for non-electric biopsy forceps, despite a further layer of scrutiny afforded by the Medical Device User Fee & Modernization Act

IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf

Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel